Gilead to present lenacapavir HIV trial data at AIDS 2026
Go back to Gilead to present lenacapavir HIV trial data at AIDS 2026| Gilead Sciences (NASDAQ: GILD) | Delayed: 146.68 -4.32 (2.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $151.00 | 52 Week High | $108.63 | |||
| Open | $146.98 | 52 Week Low | $71.39 | |||
| Day High | $148.65 | P/E | 81.04 | |||
| Day Low | $145.45 | EPS | $1.81 | |||
| Volume | 2,975,505 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 148.49 -1.84 (1.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.33 | 52 Week High | $65.46 | |||
| Open | $148.41 | 52 Week Low | $47.97 | |||
| Day High | $149.60 | P/E | 101.01 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 5,601,327 | |||||
